Simulations Plus (NASDAQ:SLP – Get Free Report) issued an update on its FY24 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of $0.66-0.68 for the period, compared to the consensus estimate of $0.67. The company issued revenue guidance of $66-69 million, compared to the consensus revenue estimate of $66.99 million. Simulations Plus also updated its FY 2024 guidance to $0.66-$0.68 EPS.
Simulations Plus Trading Up 0.3 %
SLP opened at $39.08 on Friday. The company has a market cap of $779.26 million, a P/E ratio of 79.76 and a beta of 0.61. The business’s 50-day moving average price is $39.24 and its 200-day moving average price is $43.35. Simulations Plus has a 12 month low of $32.58 and a 12 month high of $52.69.
Simulations Plus (NASDAQ:SLP – Get Free Report) last released its quarterly earnings data on Wednesday, October 25th. The technology company reported $0.18 EPS for the quarter, hitting the consensus estimate of $0.18. Simulations Plus had a return on equity of 7.68% and a net margin of 16.67%. The firm had revenue of $15.60 million for the quarter, compared to the consensus estimate of $16.94 million. During the same quarter in the previous year, the business earned $0.07 earnings per share. The company’s quarterly revenue was up 33.3% on a year-over-year basis. Equities research analysts forecast that Simulations Plus will post 0.66 earnings per share for the current fiscal year.
Simulations Plus Announces Dividend
Wall Street Analyst Weigh In
Separately, StockNews.com began coverage on Simulations Plus in a report on Thursday, October 5th. They set a hold rating on the stock.
Insider Transactions at Simulations Plus
In other news, Director John Kenneth Paglia sold 1,000 shares of the firm’s stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $35.25, for a total value of $35,250.00. Following the transaction, the director now directly owns 3,097 shares in the company, valued at approximately $109,169.25. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 21.30% of the company’s stock.
Institutional Investors Weigh In On Simulations Plus
A number of institutional investors and hedge funds have recently bought and sold shares of SLP. JPMorgan Chase & Co. grew its position in shares of Simulations Plus by 407.0% during the first quarter. JPMorgan Chase & Co. now owns 51,431 shares of the technology company’s stock valued at $2,622,000 after purchasing an additional 41,286 shares in the last quarter. US Bancorp DE grew its position in Simulations Plus by 233.4% in the first quarter. US Bancorp DE now owns 4,171 shares of the technology company’s stock worth $212,000 after acquiring an additional 2,920 shares in the last quarter. Citigroup Inc. grew its position in Simulations Plus by 15.0% in the first quarter. Citigroup Inc. now owns 13,821 shares of the technology company’s stock worth $705,000 after acquiring an additional 1,805 shares in the last quarter. PNC Financial Services Group Inc. grew its position in Simulations Plus by 12.6% in the first quarter. PNC Financial Services Group Inc. now owns 10,851 shares of the technology company’s stock worth $552,000 after acquiring an additional 1,212 shares in the last quarter. Finally, MetLife Investment Management LLC grew its position in Simulations Plus by 56.6% in the first quarter. MetLife Investment Management LLC now owns 8,535 shares of the technology company’s stock worth $435,000 after acquiring an additional 3,084 shares in the last quarter. 74.41% of the stock is owned by institutional investors.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.
- Five stocks we like better than Simulations Plus
- Dividend Payout Ratio Calculator
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- Energy and Oil Stocks Explained
- MarketBeat Week in Review – 11/13 – 11/17
- Stock Market Sectors: What Are They and How Many Are There?
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.